Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (ORIGINAL) A compound represented by the following Formula (I):



(I)

wherein:

R, R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, $-(CH_2)_pOR^4$, $-C(O)OR^4$, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, $-S(O)_nR^4$, cycloalkyl, $-NR^5R^6$, protected –OH, $-CONR^5R^6$, phosphonic acid, sulfonic acid, phosphinic acid, $-SO_2NR^5R^6$, a heterocyclic methylene substituent as represented by Formula (III),



(III),

and

a substituent as represented by Formula (VII),



(VII)

where,

p is 0-6,

n is 0-2,

W and Z are each independently selected from C, O, S and NR^{16}, where R^{16} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

V and X are each independently selected from O, S and NR^{16}, where R^{16} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

R^4 is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

R^5 and R^6 are each independently selected from hydrogen, alkyl, substituted alkyl, C_3-$_6$cycloalkyl, and aryl,

or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

T is absent or selected from O, S and NR^{16}, where R^{16} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

P is selected from OR^4, SR^4, NR^5R^6, and R^4, where R^4 is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

R^{25} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and

R^{30} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl;

R^{15} is selected from the group consisting of alkyl, C_1-C_{12}aryl, hydroxy, alkoxy, substituted alkyl, substituted C_1-C_{12}aryl and halogen;

m is 0-6; and

Y is a cyclic or polycyclic, unsaturated or saturated, non-aromatic ring containing from 3 to 16 carbon atoms and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, -$C(O)OR^4$, -$C(O)NR^{10}R^{11}$, -$S(O)_2NR^{10}R^{11}$, -$S(O)_nR^4$ and protected -OH,
where n is 0-2,
R^4 is hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and
R^{10} and R^{11} are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -$C(O)OR^4$, -$S(O)_nR^4$, -$C(O)NR^4R^4$, -$S(O)_2NR^4R^4$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,
or R^{10} and R^{11} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,
where R^4 is as described above and n is 0-2;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof;

provided that at least one of R, R^1, R^2 and R^3 is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III) or a substituent as represented in Formula (VII).

2. (ORIGINAL) A compound of claim 1 represented by the following Formula (II):



(II)

wherein:

R, R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, $-(CH_2)_pOR^4$, $-C(O)OR^4$, formyl, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, $-S(O)_nR^4$, cycloalkyl, $-NR^5R^6$, protected –OH, $-CONR^5R^6$, phosphonic acid, sulfonic acid, phosphinic acid, $-SO_2NR^5R^6$, a heterocyclic methylene substituent as represented by Formula (III),



(III),

and

a substituent as represented by Formula (VII),



(VII)

where,

p is 0-6,

n is 0-2,

W and Z are each independently selected from C, O, S and NR^{16}, where R^{16} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

V and X are each independently selected from O, S and NR^{16}, where R^{16} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

R^4 is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

R^5 and R^6 are each independently selected from hydrogen, alkyl, substituted alkyl, C_3-$_6$cycloalkyl, and aryl,

or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

T is absent or selected from O, S and NR^{16}, where R^{16} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

P is selected from OR^4, SR^4, NR^5R^6, and R^4, where R^4 is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl,

R^{25} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and

R^{30} is selected from: hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl;

R^{15} is selected from the group consisting of alkyl, C_1-C_{12}aryl, hydroxy, alkoxy, substituted alkyl, substituted C_1-C_{12}aryl and halogen;

m is 0-6; and

Y is a cyclic or polycyclic, unsaturated or saturated, non-aromatic ring containing from 5 to 14 carbon atoms and optionally substituted with one or more substituents selected from the group

consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, -$C(O)OR^4$, $-C(O)NR^{10}R^{11}$, $-S(O)_2NR^{10}R^{11}$, $-S(O)_nR^4$ and protected -OH,

where n is 0-2,

R^4 is hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and

R^{10} and R^{11} are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^4$, $-S(O)_nR^4$, $-C(O)NR^4R^4$, $-S(O)_2NR^4R^4$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

or R^{10} and R^{11} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

where R^4 is as described above and n is 0-2;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof;

provided that at least one of R, R^1, R^2 and R^3 is a substituted aryl group or a heterocyclic methylene substituent as represented in Formula (III) or a substituent as represented in Formula (VII).

3. (ORIGINAL) A compound represented by Formula (II), as defined in claim 2, wherein:

R is a substituted aryl; and R^1 is hydrogen;

R is hydrogen; and R^1 is a substituted aryl;

R is a hydrogen; and R^1 is a substituent as represented in Formula (III); or

R is a hydrogen; and R^1 is a substituent as represented in Formula (VII);

and in each of the above cases:

R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, cycloalkyl, phosphonic acid, phosphinic acid and sulfonic acid;

R^{15} is selected from the group consisting of alkyl, substituted alkyl, C_1-C_{12}aryl, alkoxy and halogen;

m is 0-4; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where the cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C_1-C_{12}aryl, substituted C_1-C_{12}aryl, alkoxy and halogen;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

4. (ORIGINAL) A compound represented by Formula (II), as defined in claim 2, wherein:

R is a substituted C_1-C_{12}aryl; and R^1 is hydrogen;

R is a hydrogen; and R^1 is a substituent as represented in Formula (III); or

R is a hydrogen; and R^1 is a substituent as represented in Formula (VII);

and in each of the above cases:

R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, nitro, cyano, halogen, substituted alkyl and cycloalkyl;

R^{15} is selected from the group consisting of alkyl, substituted alkyl, C_1-C_{12}aryl, alkoxy and halogen;

m is 0-2; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where the cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C_1-C_{12}aryl, substituted C_1-C_{12}aryl, alkoxy and halogen;

and additionally, when R is a hydrogen; and R^1 is a substituent as represented in Formula (VII);

R^{25} and R^{30} are each selected from: hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, substituted C_{1-6}alkyl and cycloalkyl;

and additionally, when R is a hydrogen; and R^1 is a substituent as represented in Formula (VII); and when R is a hydrogen; and R^1 is a substituent as represented in Formula (III);

R^4 is selected from: hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, substituted C_{1-6}alkyl and cycloalkyl; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

5. (ORIGINAL) A compound represented by Formula (II), as defined in claim 2, wherein:

R is a substituted phenyl ring and R^1 is hydrogen; or

R is a hydrogen; and R^1 is a substituent as represented in Formula (III);

and in either of the above cases:

R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, substituted alkyl and halogen;

R^{15} is selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkoxy, C_1-C_{12}aryl and halogen;

m is 0; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C_1-C_{12}aryl, substituted C_1-C_{12}aryl, alkoxy and halogen;

and additionally, when R is a hydrogen; and R^1 is a substituent as represented in Formula (III);

R^4 is selected from: hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, substituted C_{1-6}alkyl and cycloalkyl;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

6. (ORIGINAL) A compound of claim 1 selected from:

3'-(1-Cyclohexyl-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)-2'-hydroxy-biphenyl-3-carboxylic acid;

3'-[1-(4-tert-Butyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-2'-hydroxy-biphenyl-3-carboxylic acid;

3'-[1-(3,4-Dimethyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-2'-hydroxy-biphenyl-3-carboxylic acid;

3'-[1-(3,4-Dichloro-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-2'-hydroxy-biphenyl-3-carboxylic acid;

5-[4-(1-Cyclohexyl-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)-3-hydroxy-benzylidene]-thiazolidine-2,4-dione;

5-{4-[1-(4-tert-Butyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

5-{4-[1-(3,4-Dimethyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

5-{4-[1-(3,4-Dichloro-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

(E)-3-{4-[1-(4-tert-butylcyclohexyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylazo]-3-hydroxyphenyl}-2-methylacrylic acid;

(E)-3-(4-{N'-3-Ethylcyclopentyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]-hydrazino}-3-hydrophenyl-2-methylacrylic acid; and

(E)-3-[4-(N'-{1-[3-(1,1-Dimethylpropyl)-cyclopentyl]-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene}-hydrazino)-3-hydroxyphenyl]-2-methylacrylic acid;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

7. (ORIGINAL) A compound of claim 1 which is

3'-[N'-(1-cyclohexyl-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene)-hydrazino]-2'-hydroxy-biphenyl-3-carboxylic acid;

or pharmaceutically acceptable salt, hydrate, solvate and ester thereof.

8. (ORIGINAL) A method of treating of thrombocytopenia in a mammal, including a human, in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Formula (I), as described in claim 1.

9. (ORIGINAL) A method as claimed in claim 8, wherein the mammal is a human.

10. (ORIGINAL) The method of claim 9 wherein the compound is selected from the compounds listed in claim 6.

Claims 11 to 13 (CANCELLED).

14. (ORIGINAL) A pharmaceutical composition for use in enhancing platelet production which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.

Claims 15 to 18 (CANCELLED).

19. (ORIGINAL) A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of the Formula (I) as described in claim 1 and pharmaceutically acceptable salts, hydrates, solvates and esters thereof which process comprises bringing the compound of the Formula (I) into association with the pharmaceutically acceptable carrier or diluent.

20. (ORIGINAL) A process for preparing a compound of Formula (II) by reaction of a compound of Formula (XX)



(XX)

or a protected form thereof with a compound of Formula (XXI) or tautomeric equivalent (XXII)



(XXI)



(XXII)

wherein

R is a substituted aryl; and R^1 is hydrogen;

R is hydrogen; and R^1 is a substituted aryl;

R is a hydrogen; and R^1 is a substituent as represented in Formula (III); or

R is a hydrogen; and R^1 is a substituent as represented in Formula (VII);

and in each of the above cases:

R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, nitro, cyano, halogen, aryl, substituted aryl, substituted alkyl, cycloalkyl, phosphonic acid, phosphinic acid and sulfonic acid;

R^{15} is selected from the group consisting of alkyl, substituted alkyl, C_1-C_{12}aryl, alkoxy and halogen;

m is 0-4; and

Y is selected from,

cyclohexyl, cyclopentyl and cycloheptyl, where the cyclohexyl, cyclopentyl and cycloheptyl are optionally substituted with from one to three substituents selected from the group consisting of: alkyl, substituted alkyl, C_1-C_{12}aryl, substituted C_1-C_{12}aryl, alkoxy and halogen;

followed if necessary or desired by salt formation.

Claims 21 to 37 (CANCELLED).

38. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to myelosuppression caused by chemotherapy or radiation therapy.

39. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to an organ transplant.

40. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to bone marrow, stem cell, or liver transplant.

41. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to idiopathic thrombocytopenia purpura (ITP).

42. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to myelodysplastic syndromes (MDS), aplastic anemia or leukemia.

43. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to viral, fungal, microbial or parasitic infection.

44. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to liver dysfunction.

45. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to surgical procedures.

46. (ORIGINAL) A method of claim 8 wherein said thrombocytopenia is due to treatment with antiviral or antibiotic agents.

Claims 47 and 48 (CANCELLED).

49. (ORIGINAL) A compound of Claim 6 selected from:

3'-[N'-(1-cyclohexyl-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene)-hydrazino]-2'-hydroxy-biphenyl-3-carboxylic acid;

or pharmaceutically acceptable salt, hydrate, solvate and ester thereof.

50. (CANCELLED)

51. (ORIGINAL) A compound of claim 1 selected from:

3'-(1-Cyclohexyl-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo)-2'-hydroxy-biphenyl-3-carboxylic acid;

5-{4-[1-(4-tert-Butyl-cyclohexyl)-5-hydroxy-3-methyl-1H-pyrazol-4-ylazo]-3-hydroxy-benzylidene}-thiazolidine-2,4-dione;

(E)-3-{4-[1-(4-tert-butylcyclohexyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylazo]-3-hydroxyphenyl}-2-methylacrylic acid;

(E)-3-(4-{N'-3-Ethylcyclopentyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]-hydrazino}-3-hydrophenyl-2-methylacrylic acid; and

(E)-3-[4-(N'-{1-[3-(1,1-Dimethylpropyl)-cyclopentyl]-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene}-hydrazino)-3-hydroxyphenyl]-2-methylacrylic acid;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.